Trial Profile
A Phase I/II Multi-Center Study of Weekly Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) in Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed a Prior Platinum-Containing Regimen
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Oct 2005
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Exisulind (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Oct 2005 New trial record.